BeiGene, Ltd. (NASDAQ:BGNE) Receives $253.69 Average Target Price from Brokerages

BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $253.69.

Several brokerages have recently issued reports on BGNE. JMP Securities started coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price objective on the stock. TD Cowen lifted their price target on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd. Morgan Stanley restated an "overweight" rating and issued a $300.00 target price on shares of BeiGene in a report on Tuesday, December 3rd. Finally, StockNews.com downgraded BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st.

Insider Buying and Selling

In related news, insider Lai Wang sold 5,000 shares of the business's stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $220.35, for a total transaction of $1,101,750.00. Following the transaction, the insider now directly owns 920,920 shares of the company's stock, valued at approximately $202,924,722. The trade was a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,131,622 shares of company stock valued at $212,520,787. Corporate insiders own 7.43% of the company's stock.

Hedge Funds Weigh In On BeiGene

Several institutional investors have recently bought and sold shares of BGNE. Blue Trust Inc. boosted its holdings in BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after purchasing an additional 75 shares during the period. Raymond James & Associates lifted its stake in shares of BeiGene by 0.4% in the second quarter. Raymond James & Associates now owns 21,275 shares of the company's stock valued at $3,035,000 after buying an additional 76 shares during the period. Truist Financial Corp grew its position in BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company's stock worth $217,000 after buying an additional 140 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in BeiGene during the third quarter worth about $36,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in BeiGene by 0.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company's stock valued at $21,978,000 after acquiring an additional 266 shares during the period. 48.55% of the stock is currently owned by institutional investors.

BeiGene Price Performance

NASDAQ BGNE traded up $3.92 on Wednesday, reaching $181.62. 148,370 shares of the stock traded hands, compared to its average volume of 284,126. BeiGene has a 12 month low of $126.97 and a 12 month high of $248.16. The company has a market cap of $17.71 billion, a price-to-earnings ratio of -22.04 and a beta of 0.57. The firm's fifty day simple moving average is $199.18 and its 200 day simple moving average is $188.30. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company's quarterly revenue was up 28.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. As a group, research analysts predict that BeiGene will post -5.64 EPS for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.